Beijing Qingyi Taike Pharma

Beijing Qingyi Taike Pharma is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the development of small molecule drugs for oncology. The company focuses on the Hippo signaling pathway, particularly targeting the TEA domain (TEAD) transcription factors to treat cancers with specific genetic alterations such as NF2 mutations. Its lead candidate, T-101, is a potent and selective TEAD inhibitor currently undergoing clinical evaluation for solid tumors including mesothelioma and meningioma. By integrating structural biology and advanced medicinal chemistry, Qingyi Taike aims to deliver innovative therapies for previously undruggable targets in the cancer field. The company was founded by experts from Tsinghua University and has secured significant venture capital funding to advance its pipeline of Hippo-YAP/TAZ pathway modulators.